ABSTRACT
ABSTRACT Choroid plexus papillomas (CPP) are a rare oncological condition. They affect mostly the pediatric population, and the diagnosis is associated with clinical findings, imaging and anatomopathological methods. We report the case of a 49-year-old woman who underwent neurosurgical evaluation for chronic headache and emotional stress. CPP is a rare central nervous system tumor in the adult population. We present, therefore, a case in an adult female, whose diagnosis was confirmed by histopathology methods. Surgical treatment is the gold standard, showing full resolution in almost all cases.
RESUMEN Los papilomas de los plexos coroideos (PPC) son una condición oncológica bastante rara. Acometen mayormente la población pediátrica; su diagnóstico implica un análisis clínico asociado a los métodos de imagen y anatomopatológico. Reportamos el caso de una mujer de 49 anos atendida para evaluación neuroquirúrgica con cefalea crónica y estrés emocional. El PPC es un tumor delsistema nervioso central sumamente raro en la población adulta. Así, presentamos un caso raro en una mujer adulta, cuyo diagnóstico fue confirmado por métodos histopatológicos. El tratamiento quirúrgico es el estándar de oro, ya que muestra resolución completa en casi todos los casos.
RESUMO Os papilomas do plexo coroide (PPC) são uma condição oncológica bastante rara. Acometem majoritariamente a população pediátrica; seu diagnóstico envolve uma análise clínica associada aos métodos de imagem e anatomopatológico. Relatamos o caso de uma mulher de 49 anos atendida no Hospital das Clínicas da Universidade Federal de Goiás (UFG) para avaliação neurocirúrgica com clínica de cefaleia crônica e estresse emocional. O PPC é um tumor do sistema nervoso central extremamente raro na população adulta. Apresentamos, portanto, um caso raro em uma mulher adulta, cujo diagnóstico foi confirmado por métodos histopatológicos. O tratamento cirúrgico é o padrão-ouro, pois mostra resolução completa em quase todos os casos.
ABSTRACT
Calls for institutional investors to divest (sell off) tobacco stocks threaten the industry's share values, publicise its bad behaviour, and label it as a politically unacceptable ally. US tobacco control advocates began urging government investment and pension funds to divest as a matter of responsible social policy in 1990. Following the initiation of Medicaid recovery lawsuits in 1994, advocates highlighted the contradictions between state justice departments suing the industry, and state health departments expanding tobacco control programmes, while state treasurers invested in tobacco companies. Philip Morris (PM), the most exposed US company, led the divestment opposition, consistently framing the issue as one of responsible fiscal policy. It insisted that funds had to be managed for the exclusive interest of beneficiaries, not the public at large, and for high share returns above all. This paper uses tobacco industry documents to show how PM sought to frame both the rhetorical contents and the legal contexts of the divestment debate. While tobacco stock divestment was eventually limited to only seven (but highly visible) states, US advocates focused public attention on the issue in at least 18 others plus various local jurisdictions. This added to ongoing, effective campaigns to denormalise and delegitimise the tobacco industry, dividing it from key allies. Divestment as a delegitimisation tool could have both advantages and disadvantages as a tobacco control strategy in other countries.
Subject(s)
Conflict of Interest , Financial Management/standards , Social Responsibility , Tobacco Industry/economics , Government , Humans , Investments , Persuasive Communication , United States , Universities/economicsABSTRACT
Clients in substance abuse treatment are at high risk for smoking-related illness due to higher rates and heavier smoking than the general population. Three myths widely held by both treatment staff and substance abusers in treatment-people in treatment do not want to quit smoking, people in treatment will relapse to other drug use if they attempt to quit smoking, and people in treatment are unable to quit smoking-make it difficult to broach the matter of smoking cessation. A 16-week, cognitive-behavioral group program with nicotine patches was conducted at Oregon's largest, private, nonprofit substance abuse treatment agency. Of 490 clients, approximately 85% of whom smoke, 106 (25% of the smokers) were interested enough in quitting to attend an orientation. Approximately 40% of these were methadone maintenance clients. The others were distributed among two residential and two outpatient drug-free treatment services. Of 90 assigned, 68 began voluntary treatment, and 21 were assigned to delayed treatment. Of the 66 smokers who began, 74% succeeded in quitting smoking for at least 1 day, and 23% were abstinent for at least 4 continuous weeks. At the end of the 16-week treatment, 7 subjects (11%) were abstinent. No control subjects quit smoking on their own. The article discusses issues of institutionalizing smoking cessation services in drug treatment agencies.
